X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with AANJANEYA LIFECARE - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs DR. DATSONS LABS - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA DR. DATSONS LABS ASTRAZENECA PHARMA/
DR. DATSONS LABS
 
P/E (TTM) x 104.8 -10.9 - View Chart
P/BV x 14.9 0.2 9,195.2% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ASTRAZENECA PHARMA   DR. DATSONS LABS
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
DR. DATSONS LABS
Mar-14
ASTRAZENECA PHARMA/
DR. DATSONS LABS
5-Yr Chart
Click to enlarge
High Rs1,285126 1,023.1%   
Low Rs63431 2,051.8%   
Sales per share (Unadj.) Rs189.6133.0 142.6%  
Earnings per share (Unadj.) Rs-0.20.2 -134.3%  
Cash flow per share (Unadj.) Rs3.86.6 58.2%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs68.6128.8 53.3%  
Shares outstanding (eoy) m25.0031.66 79.0%   
Bonus/Rights/Conversions -FCCB-  
Price / Sales ratio x5.10.6 860.1%   
Avg P/E ratio x-4,712.7516.1 -913.1%  
P/CF ratio (eoy) x249.611.8 2,107.6%  
Price / Book Value ratio x14.00.6 2,300.7%  
Dividend payout %00-   
Avg Mkt Cap Rs m23,9882,477 968.3%   
No. of employees `0001.6NA-   
Total wages/salary Rs m1,60556 2,865.4%   
Avg. sales/employee Rs Th3,040.2NM-  
Avg. wages/employee Rs Th1,029.2NM-  
Avg. net profit/employee Rs Th-3.3NM-  
INCOME DATA
Net Sales Rs m4,7404,211 112.6%  
Other income Rs m9279 117.0%   
Total revenues Rs m4,8324,289 112.7%   
Gross profit Rs m-130569 -22.8%  
Depreciation Rs m101204 49.5%   
Interest Rs m0430 0.0%   
Profit before tax Rs m-13913 -1,093.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m56 83.4%   
Profit after tax Rs m-55 -106.0%  
Gross profit margin %-2.713.5 -20.3%  
Effective tax rate %-3.748.0 -7.6%   
Net profit margin %-0.10.1 -94.2%  
BALANCE SHEET DATA
Current assets Rs m2,7266,852 39.8%   
Current liabilities Rs m2,4356,711 36.3%   
Net working cap to sales %6.13.3 183.6%  
Current ratio x1.11.0 109.7%  
Inventory Days Days74161 45.9%  
Debtors Days Days41318 12.8%  
Net fixed assets Rs m1,0353,673 28.2%   
Share capital Rs m50317 15.8%   
"Free" reserves Rs m9423,761 25.1%   
Net worth Rs m1,7164,078 42.1%   
Long term debt Rs m01,671 0.0%   
Total assets Rs m4,15612,633 32.9%  
Interest coverage xNM1.0-  
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x1.10.3 342.2%   
Return on assets %-0.13.4 -3.6%  
Return on equity %-0.30.1 -252.0%  
Return on capital %07.7 0.0%  
Exports to sales %5.722.9 24.9%   
Imports to sales %6.514.3 45.2%   
Exports (fob) Rs m270964 28.0%   
Imports (cif) Rs m306602 50.9%   
Fx inflow Rs m375964 38.9%   
Fx outflow Rs m470607 77.4%   
Net fx Rs m-96357 -26.8%   
CASH FLOW
From Operations Rs m-81,345 -0.6%  
From Investments Rs m-146-2,256 6.5%  
From Financial Activity Rs m862-1,200 -71.9%  
Net Cashflow Rs m709-2,111 -33.6%  

Share Holding

Indian Promoters % 0.0 4.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 0.0 -  
FIIs % 15.7 1.4 1,163.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 94.1 9.7%  
Shareholders   12,856 20,807 61.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   CIPLA  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  SHASUN PHARMA  PFIZER  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Firm; Software & FMCG Stocks Gain(Closing)

Indian share markets finished the trading session well above the dotted line, snapping a three-day falling streak amid firm Asian markets.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Feb 21, 2018 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS